Benzinga | Jul 21, 2021 07:24PM EDT

EXCLUSIVE: Lexaaria Biosciences CEO Chris Bunka Tells Benzinga that Use of DehydraTECH-enabled Colchcine Results in Increased Drug Delivery and Concentration Into the Bloodstream by 167% and 91% Respectively in Mitigating the Cytokine Storm Associated with SARS-CoV-2/COVID-19

Lexaria issued a press release earlier today regarding possible benefits of DehydraTECH-enabled Colchcine for treating SARS-CoV-2/COVID-19 and mRNA vaccine side effects